Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIT: Ranibizumab vs Methotrexate vs Dexamethasone for Uveitic Macular Edema
NCT02623426Phase 3Completed
- Sponsor
- Johns Hopkins Center for Clinical Trials and Evidence Synthesis
- Start
- Mar 2017
- Primary completion
- Oct 2021
- Modality
- Antibody Fragments, Antibody Conjugates, Implantable Devices
- Countries
- 5
01
Overview
Phase 3, randomised, single-blind trial in uveitic macular edema (UME) comparing Ozurdex, Methotrexate and Lucentis (3 arms). Primary endpoint: Percent change in central subfield thickness at 12 weeks. Started Mar 2017; status: completed.
02
Drugs
methotrexateranibizumabozurdex
03
Conditions
uveitic macular edema (UME)
Beyond the preview
Go deeper on NCT02623426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623426.